Eurobio Scientific SA
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monito… Read more
Eurobio Scientific SA - Asset Resilience Ratio
Eurobio Scientific SA (ALERS) has an Asset Resilience Ratio of 10.52% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Eurobio Scientific SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Eurobio Scientific SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €26.86 Million | 10.37% |
| Short-term Investments | €393.00K | 0.15% |
| Total Liquid Assets | €27.25 Million | 10.52% |
Asset Resilience Insights
- Moderate Liquidity: Eurobio Scientific SA has 10.52% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Eurobio Scientific SA Industry Peers by Asset Resilience Ratio
Compare Eurobio Scientific SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for Eurobio Scientific SA (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Eurobio Scientific SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.47% | €24.36 Million | €257.17 Million | -31.23pp |
| 2023-12-31 | 40.70% | €128.76 Million | €316.33 Million | +3.06pp |
| 2022-12-31 | 37.64% | €124.38 Million | €330.42 Million | -15.82pp |
| 2021-12-31 | 53.46% | €111.85 Million | €209.22 Million | +15.15pp |
| 2020-12-31 | 38.31% | €66.01 Million | €172.30 Million | +28.16pp |
| 2019-12-31 | 10.15% | €8.22 Million | €81.01 Million | -7.19pp |
| 2018-12-31 | 17.34% | €12.12 Million | €69.90 Million | -1.02pp |
| 2017-12-31 | 18.36% | €13.14 Million | €71.57 Million | -8.91pp |
| 2016-12-31 | 27.27% | €8.70 Million | €31.89 Million | +7.39pp |
| 2015-12-31 | 19.88% | €7.10 Million | €35.71 Million | -7.64pp |
| 2014-12-31 | 27.52% | €11.14 Million | €40.50 Million | +19.90pp |
| 2013-12-31 | 7.62% | €2.55 Million | €33.41 Million | -0.55pp |
| 2012-12-31 | 8.16% | €3.14 Million | €38.49 Million | -22.12pp |
| 2011-12-31 | 30.28% | €5.33 Million | €17.60 Million | -35.12pp |
| 2010-12-31 | 65.40% | €20.45 Million | €31.26 Million | -11.60pp |
| 2009-12-31 | 77.00% | €28.14 Million | €36.55 Million | +25.39pp |
| 2008-12-31 | 51.61% | €15.40 Million | €29.85 Million | -14.74pp |
| 2007-12-31 | 66.34% | €24.94 Million | €37.59 Million | -- |